Potential use of gene transfer in athletic performance enhancement

Molecular Therapy

Volumn 15, Issue 10, 2007, Pages 1751-1766

  Baoutina, Anna ^a   Alexander, Ian E ^b   Rasko, John E J ^c   Emslie, Kerry R ^a  

^a NATIONAL MEASUREMENT INSTITUTE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC PROTEIN; ANGIOPOIETIN 1; BLOOD CLOTTING FACTOR 9; BONE MORPHOGENETIC PROTEIN 2; FIBROBLAST GROWTH FACTOR; FOLLISTATIN; GLUTAMATE DECARBOXYLASE; GROWTH FACTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MITOCHONDRIAL PROTEIN; MUSCLE GROWTH FACTOR; MYOSTATIN; NAKED DNA; NARCOTIC ANALGESIC AGENT; ORNITHINE CARBAMOYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT SOMATOMEDIN C; RETROVIRUS VECTOR; SOMATOMEDIN C; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANALGESIA; ANGIOGENIC GENE THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; BONE REMODELING; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOPING; DRUG FATALITY; DRUG MECHANISM; DRUG MISUSE; DRUG SAFETY; DRUG TOLERANCE; EDEMA; FRACTURE; GENE DOPING; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEALTH EDUCATION; HEMATOLOGIC DISEASE; HUMAN; HYDRODYNAMICS BASED TRANSFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEUKEMIA; LUNG TOXICITY; MULTIPLE ORGAN FAILURE; MUSCLE ATROPHY; MUSCLE INJURY; MUSCLE REGENERATION; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHYSICAL PERFORMANCE; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SPORTING EVENT; T CELL LEUKEMIA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION;

DOPING IN SPORTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS;

ANIMALIA;

EID: 34548723321     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300278     Document Type: Review

References (141)

1. World Anti-Doping Agency. (2005) The world anti-doping code. The 2006 prohibited list. WADA . Accessed April 2007.
2. Schneider, AJ and Friedmann, T (2006). Gene doping in sports: The science and ethics of genetically modified athletes. Adv Genet 51: 1-110.
3. Haisma, HJ and de Hon, O (2006). Gene doping. Int J Sports Med 27: 257-266.
4. Miah, A (2006). Rethinking enhancement in sport. Ann NY Acad Sci 1093: 301-320.
5. Azzazy, HM, Mansour, MM and Christenson, RH (2005). Doping in the recombinant era: Strategies and counterstrategies. Clin Biochem 38: 959-965.
6. Rasko, JEJ, O'Sullivan, GM and Ankeny, RA (2006) The Ethics of Inheritable Genetic Modification. Cambridge University Press: Cambridge.
7. Dykxhoom, DM and Lieberman, J (2006). Knocking down disease with siRNAs. Cell 126: 231-235.
8. Fichou, Y and Ferec, C (2006). The potential of oligonucleotides for therapeutic applications. Trends Biotechnol 24: 563-570.
9. Gommans, WM, Haisma, HJ and Rots, MG (2005). Engineering zinc finger protein transcription factors: The therapeutic relevance of switching endogenous gene expression on or off at command. J Mol Biol 354 507-519.
10. Umov, FD, Miller, JC, Lee, YL, Beausejour, CM, Rock, JM, Augustus, S et al. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435: 646-651.
11. McClorey, G, Fall, AM, Moulton, HM, Iversen, PL, Rasko, JE, Ryan, M et al. (2006). Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16: 583-590.
12. McMahon, JM and Wells, DJ (2004). Electroporation for gene transfer to skeletal muscles: Current status. BioDrugs 18: 155-165.
13. Mir, LM, Moller, PH, Andre, F and Gehl, J (2005). Electric pulse-mediated gene delivery to various animal tissues. Adv Genet 54: 83-114.
14. Dal, Q, Huang, J, Klitzman, B, Dong, C, Goldschmidt-Clermont PJ, March, KL et al. (2004). Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmild DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 110: 2457-2475.
15. Xie, D, Li Y, Reed, EA, Odronic, SI, Kontos, CD and Annex, BH (2006). An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J Vasc Surg 44: 166-175.
16. Oh, TK, Quan, GH, Kim, HY, Park, F and Kim, ST (2006). Correction at anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol 26: 326-334.
17. Seppen, J, Barry, SC, Harder, B and Osborne, WR (2001). Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 98: 594-596.
18. Rivera, VM, Ye, X, Courage, NL, Sachar, J, Cerasoli F, Wilson, JM et al. (1999). Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci USA 96 8657-8662.
19. Zoltick, PW, Chirmule, N, Schnell, MA, Gao, GP, Hughes, JV, Wilson, JM et al. (2001). Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol 75: 5222-5229.
20. Menezes, KM, Mok, HS and Barry, MA (2006). Increased transduction of skeletal muscle cells by fibroblast growth factor-modified adenoviral vectors. Hum Gene Ther 17: 314-320.
21. Chirmule, N, Xiao, W, Truneh, A, Schnell, MA, Hughes, JV, Zoltick, P et al. (2000). Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 74: 2420-2425.
22. Payumo, FC, Kim, HD, Sherling, MA, Smith, LP, Powell, C, Wang, X et al.(2002). Tissue engineering skeletal muscle for arthopaedic applications. Clin Orthop Relat Res (403 suppl.): S228-S242.
23. Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972.
24. Morishita, R, Aoki, M, Hashiya, N, Makino, H, Yamasaki, K, Azuma, J et al. (2004). Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44: 203-209.
25. Yeh, JL and Giordano, FJ (2003). Gene-based therapeutic angiogenesis. Semin Thorac Cardiovasc Surg 15: 236-249.
26. Shah, PB and Losordo, DW (2005). Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. Adv Genet 54: 339-361.
27. Rajagopalan, S, Mohler, ER, Lederman, RJ, Mendelsohn, FO, Saucedo, JF, Goldman, CK et al. (2003). Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938.
28. Al-Dosari, MS, Knapp, JE and Liu, D (2005). Hydrodynamic delivery. Adv Genet 54: 65-82.
29. Hagstrom, JE, Hegge, J, Zhang, G, Noble, M, Budker, V, Lewis, DL et al. (2004). A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 10 386-398.
30. Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 110: 828-834.
31. High, K (2005). Gene transfer for hemophilia: Can therapeutic efficacy in large animals be safely translated to patients? J Thromb Haemost 3: 1682-1691.
32. Arruda, VR, Stedman, HH, Nichols, TC, Haskins, ME, Nicholson, M, Herzog, RW et al. (2005). Regional intravascular delivery of AAV-2-FIX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105: 3458-3464.
33. Papadakis, ED, Nicklin, SA, Baker, AH and White, SJ (2004). Promoters and control elements: Designing expression cassettes for gene therapy. Curr Gene Ther 4: 89-113.
34. Yew, NS (2005). Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev 57: 769-780.
35. Cavazzana-Calvo, M, Lagresle, C, Hacein-Bey-Abina, S and Fischer, A (2005). Gene therapy for severe combined immunodeficiency. Annu Rev Med 56: 585-602.
36. Ott, MG, Schmidt M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
37. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metob 80: 148-158.
38. Palmer, DH, Young, LS and Mautner, V (2006). Cancer gene-therapy: clinical trials. Trends Biotechnol 24: 76-82.
39. Manna, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Raska, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
40. Maheshri, N, Koerber, JT, Kaspar, BK and Schaffer, DV (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24: 198-204.
41. Gao, G, Lu, Y, Calcedo, R, Grant RL, Bell, P, Wang, L et al. (2006). Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13: 77-87.
42. De, BP, Heguy, A, Hackett, NR, Ferris, B, Leopold, PL, Lee, J et al. (2006). High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 13: 67-76.
43. Chenuaud, P, Larcher, T, Rabinowitz, JE, Provost, N, Cherel, Y, Casadevall, N et al. (2004). Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103: 3303-3304.
44. Gao, G, Lebherz, C, Weiner, DJ, Grant R, Calcedo, R, McCullough, B et al. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302.
45. Ribatti, D, Vacca, A, Roccaro, AM, Crivellato, E and Presta, M (2003). Erythropoietin as an angiogenic factor. Eur J Clin Invest 33 891-896.
46. Chong, ZZ and Maiese, K (2007). Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 150: 839-850.
47. Fattori, E, Cappelletti, M, Zampaglione, I, Mennuni, C, Calvaruso, F, Arcuri, M et al. (2005). Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 7: 228-236.
48. Richard, P, Pollard, H, Lanctin, C, Bello-Roufaï, M, Désigaux, L, Escande, D et al. (2005). Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation. J Gene Med 7: 80-86.
49. Hojman, P, Gissel, H and Gehl, J (2007). Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 14: 950-959.
50. Rivera, VM, Gao, GP, Grant RL, Schnell, MA, Zoltick, PW, Rozamus, LW et al. (2005). Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430.
51. Siprashvill, Z and Khavari, PA (2004). Lentivectors for regulated and reversible cutaneous gene delivery. Mol Ther 9: 93-100.
52. Mizukami, H, Mimuro, J, Ogura, T, Okada, T, Urabe, M, Kume, A et al. (2006). Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther 17 921-928.
53. Wang, J, Voutetakis, A, Papa, M, Rivera, VM, Clackson, T, Lodde, BM et al. (2006). Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands. Gene Ther 13: 187-190.
54. Gaudard, A, Varlet-Marle, E, Bressolle, F and Audran, M (2003). Drugs for increasing oxygen and their potential use in doping: A review. Sports Med 33: 187-212.
55. Lippin, Y, Dranitzki-Elhalel, M, Brill-Almon, E, Mei-Zahav, C, Mizrachi, S, Liberman, Y et al. (2005). Human erythropoietin gene therapy for patients with chronic renal failure. Blood 106: 2280-2286.
56. Orive, G, De Castro, M, Ponce, S, Hernández, RM, Gascón, AR, Bosch, M et al. (2005). Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neavascularized microcapsules. Mol Ther 12: 283-289.
57. Yanay, O, Barry, SC, Flint LY, Brzezinski, M, Barton, RW and Osborne, WR (2003). Long-term erythropoietin gene expression from transduced cells in bioisolator devices. Hum Gene Ther 14: 1587-1593.
58. Eliopoulos, N, Gagnon, RF, Francois, M and Galipeau, J (2006) Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol 17: 1676-1584.
59. Recombinant DNA advisory committee. Minutes of meeting, September 25-26, 2000. U.S. Department of Health and Human Services. National Institutes of Health . Accessed April 2007.
60. Abruzzese, RV, Godin, D, Mehta, V, Perrard, JL, French, M, Nelson, W et al. (2000). Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther 2: 276-287.
61. Binley, K, Askham, Z, Iqball, S, Spearman, H, Martin, L, de Alwis, M et al. (2002). Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 100: 2406-2413.
62. Arcasoy, MO, Karayal, AF, Segal, HM, Sinning, JG and Forget, BG (2002). A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood 99: 3066-3069.
63. de la Chapelle, A, Traskelin, AL and Juvonen, E (1993). Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci US4 90: 4495-4499.
64. Tam, BY, Wei, K, Rudge, JS, Hoffman, J, Holash, J, Park, SK et al. (2006). VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12: 793-800.
65. Lin, J, Handschin, C and Spiegelman, BM (2005). Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1: 361-370.
66. Wang, YX, Zhang, CL, Yu, RT, Cho, HK, Nelson, MC, Bayuga-Ocampo, CR et al. (2004). Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2: E294.
67. Lin, J, Wu, H, Tarr, PT, Zhang, CY, Wu, Z, Boss, O et al. (2002). Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418: 797-801.
68. Leone, TC, Lehman, JJ, Finck, BN, Schaeffer, PJ, Wende AR, Boudina, S et al. (2005). PGC-1alpha deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3: E101.
69. Arany, Z, Lebrasseur, N, Morris, C, Smith, E, Yang, W, Ma, Y et al. (2007). The transcriptional coactivator PGC-1 beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab 5: 35-46.
70. Kamei, Y, Ohizumi, H, Fujitani, Y, Nemoto, T, Tanaka, T, Takahashi, N et al. (2003). PPARgamma coactivator 1β/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci USA 100: 12378-12383.
71. Wallace, DC (2005). The mitochondrial genome in human adaptive radiation and disease: On the road to therapeutics and performance enhancement. Gene 354: 169-180.
72. Gyongyosi, M, Khorsand, A, Zamini, S, Sperker, W, Strehblow, C, Kastrup, J et al. (2005). NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: Subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112: 1157-1165.
73. Kusumanto, YH, van Weel, V, Mulder, NH, Smit, AJ, van den Dungen, JJ, Hooymans, JM et al. (2006). Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther 17: 683-691.
74. ClinicalTrials.gov - A Service of the U.S. National Institutes of Health (2007). EW-A-401 to treat intermittent Claudication. . Accessed May 2007.
75. Gene Therapy Clinical Trials World Wide (2007). The Journal of Gene Medicine Clinical Trial site. WILEY . Accessed May 2007.
76. Ho, HK, Jang, JJ, Kaji, S, Spektor, G, Fong, A, Yang, P et al. (2004). Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: Its role in ischemia. Circulation 109: 1314-1319.
77. Rajagopalan, S, Olin, JW, Young, S, Erikson, M, Grossman, PM, Mendelsohn, FO et al. (2004). Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 15: 619-624.
78. Musaro, A, McCullagh, K, Paul, A, Houghton, L, Dobrowolny, G, Molinaro, M et al. (2001). Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27: 195-200.
79. Barton-Davis, ER, Shoturma, DI, Musaro, A, Rosenthal, N and Sweeney, HL (1998). Viral mediated expression of insulin-like growth factor 1 blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 95: 15603-15607.
80. Lee, S, Barton, ER, Sweeney, HL and Farrar, RP (2004). Viral expression of insulin-like growth factor-1 enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol 96: 1097-1104.
81. Takahashi, T, Ishida, K, Itoh, K, Konishi, Y, Yagyu, KI, Tominaga, A et al. (2003). IGF-1 gene transfer by electroporation promotes regeneration in a muscle injury model. Gene Ther 10: 612-620.
82. Goldspink, G (2005). Mechanical signals, IGF-I gene splicing and muscle adaptation. Physiology (Bethesda) 20: 232-238.
83. McCroskery, S, Thomas, M, Platt, L, Hennebry, A, Nishimura, T, McLeay, L et al. (2005). Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118: 3531-3541.
84. Wagner, KR (2005). Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol 17: 720-724.
85. Lee, SJ (2004). Regulation of muscle mass by myostatin. Annul Rev Cell Dev Biol 20: 61-86.
86. Steelman, CA, Recknor, JC, Nettleton, D and Reecy, JM (2006). Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB J 20: 580-582.
87. Yang, J and Zhao, B (2006). Postnatal expression of myostatin propeptide cDNA maintained high muscle growth and normal adipose tissue mass in transgenic mice fed a high-fat diet. Mol Reprod Dev 73: 462-469.
88. Clop, A, Marcq, F, Takeda, H, Pirottin, D, Tordoir, X, Bibé, B et al. (2006). A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38: 813-818.
89. Liang, YC, Yeh, JY and Ou, BR (2007). Effect of maternal myostatin antibody on offspring growth performance and body composition in mice. J Exp Biol 210: 477-483.
90. Reisz-Porszasz, S, Bhasin, S, Artaza, JN, Shen, R, Sinha-Hikim, I, Hogue, A et al. (2003). Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 285: E876-E888.
91. Zimmers, TA, Davies, MV, Koniaris, LG, Haynes, P, Esquela, AF, Tomkinson, KN et al. (2002). Induction of cachexia in mice by systemically administered myostatin. Science 296: 1486-1488.
92. Lee, SJ and McPherron, AC (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306-9311.
93. Suryawan, A, Frank, JW, Nguyen, HV and Davis, TA (2006). Expression of the TGF-beta family of ligands is developmentally regulated in skeletal muscle of neonatal rats. Pediatr Res 59: 175-179.
94. Iezzi, S, Di Padova, M, Serra, C, Caretti, G, Simone, C, Maklan, E et al. (2004). Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 6: 673-684.
95. Matzuk, MM, Lu, N, Vogel, H, Sellheyer, K, Roop, DR and Bradley, A (1995). Multiple defects and perinatal death in mice deficient in follistatin. Nature 374: 360-363.
96. Amthor, H, Nicholas, G, McKinnell, I, Kemp, CF, Sharma, M, Kambadur, R et al. (2004). Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 270: 19-30.
97. Sutrave, P, Leferovich, JM, Kelly, AM and Hughes, SH (2000). The induction of skeletal muscle hypertrophy by a ski transgene is promoter-dependent. Gene 241: 107-116.
98. Lee, SJ, Reed, LA Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102: 18117-18122.
99. Bartoli, M, Poupiot, J, Vulin, A, Fougerousse, F, Arandel, L, Danielle, N et al. (2007). AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not α-sarcoglycan deficiency. Gene Ther 14: 733-740.
100. Acosta, J, Carpio, Y, Borroto, I, Gonzalez, O and Estrada, MP (2005). Myostatin gene silenced by RNAi show a zebrafish giant phenotype. J Biotechnol 119: 324-331.
101. Willoughby, DS (2004). Effects of an alleged myostatin-binding supplement and heavy resistance training on serum myostatin, muscle strength and mass and body composition. Int J Sport Nutr Exerc Metab 14: 461-472.
102. Willoughby, DS (2004). Effects of heavy resistance training on myostatin mRNA and protein expression. Med Sci Sports Exerc 36: 574-582.
103. Hulmi, JJ, Ahtiainen, JP, Kaasalainen, T, Pöllänen, E, Häkkinen, K, Alen, M et al. (2007). Postexercise myostatin and activin IIb mRNA levels: Effects of strength training. Med Sci Sports Exerc 39: 289-297.
104. Roth, SM, Martel, GF, Ferrell, RE, Metter, EJ, Hurley, BF and Rogers, MA (2003). Myostatin gene expression is reduced in humans with heavy-resistance strength training: A brief communication. Exp Biol Med (Maywood) 228: 706-709.
105. Kvorning, T, Andersen M, Brixen K, Schjerling P, Suetta, C and Madsen, K (2007). Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humans. J Physiol 578: 579-593.
106. Amthor, H, Macharia, R, Navarrete, R, Schuelke, M, Brown, SC, Otto, A et al. (2007). Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA 104: 1835-1840.
107. Charge, SB, Brack AS and Hughes, SM (2002). Aging-related satellite cell differentiation defect occurs prematurely after Ski-induced muscle hypertrophy. Am J Physiol Cell Physiol 283: C1228-1241.
108. De Palo, EF, De Filippis, V, Gatti, R and Spinella, P (2006). Growth hormone isoforms and segments/fragments: Molecular structure and laboratory measurement. Clin Chim Acta 364: 67-76.
109. Bidlingmaier, M, Wu, Z and Strasburger, CJ (2003). Problems with GH doping in sports. J Endocrinol Invest 26: 924-931.
110. Ehmborg, C, Ohlsson, C, Mohan, S, Bengtsson, BK and Rosen, T (2007). Increased serum concentration of IGFBP-4 and IGFBP-5 in healthy adults during one month's treatment with supraphysiological doses of growth hormone. Growth Horm IGF Res 17: 234-241.
111. Inazawa, T, Tanabe, T, Yamada, H, Nakaoka, T, Hashimoto, Y, Yamasaki, T et al. (2001). Glucocorticoid-regulated expression of exogenous human growth hormone gene in rats. Mol Ther 4: 267-272.
112. Peroni, CN, Cecchi, CR, Damiani, R, Soares, CR, Ribela, MT, do Rocio Arkaten, R et al. (2006). High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: Prospects for an animal model of cutaneous gene therapy. Mol Biotechnol 34: 239-245.
113. Goldspink G (2003). Skeletal muscle as an artificial endocrine tissue. Best Pract Res Clin Endocrinol Metab 17: 211-222.
114. Khan, AS, Brown, PA and Draghia-Akli, R (2005). Plasmid-based growth hormone-releasing hormone supplementation and its applications. Curr Opin Mol Ther 7: 306-316.
115. Khan, AS, Smith, LC, Anscombe, IW, Cummings, KK, Pope, MA, Draghla-Akli, R et al. (2005). Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice. Cancer Gene Ther 12: 54-60.
116. Lattanzi, W, Pola, E, Pecorini, G, Logroscino, CA and Robbins, PD (2005). Gene therapy for in vivo bone formation: Recent advances. Eur Rev Med Pharmacol Sci 9: 167-174.
117. Egermann, M, Schneider, E, Evans, CH and Baltzer, AW (2005). The potential of gene therapy for fracture healing in osteoporosis. Osteoporos Int 16 (suppl. 2): S120-S128.
118. Southwood, LL, Frisble, DD, Kawcak, CE and McIlwraith, CW (2004). Delivery of growth factors using gene therapy to enhance bone healing. Vet Surg 33: 565-578.
119. Egermann, M, Baltzer, AW, Adamaszek, S, Evans, C, Robbins, P, Schneider, E et al. (2006). Direct adenoviral transfer of bone morphogenetic protein-2 cDNA enhances fracture healing in osteoporotic sheep. Hum Gene Ther 17: 507-517.
120. Egermann, M, Lill, CA, Griesbeck, K, Evans, CH, Robbins, PD, Schneider, E et al. (2006). Effect of BMP-2 gene transfer on bone healing in sheep. Gene Ther 13: 1290-1299.
121. Lieberman, JR, Ghivizzani, SC and Evans, CH (2002). Gene transfer approaches to the healing of bone and cartilage. Mol Ther 6: 141-147.
122. Cucchiarini, M and Madry, H (2005). Gene therapy for cartilage defects. J Gene Med 7: 1495-1509.
123. Kaul, G, Cucchiarini, M, Amtzen, D, Zurakowski, D, Menger, MD, Kohn, D et al. (2006). Local stimulation of articular cartilage repair by transplantation of encapsulated chondrocytes overexpressing human fibroblast growth factor 2 (FGF-2) in vivo. J Gene Med 8: 100-111.
124. Goodrich, LR, Brower-Toland, BD, Warnick, L, Robbins, PD, Evans, CH and Nixon, AJ (2006). Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations. Gene Ther 13: 1253-1262.
125. Hiraide, A, Yokoo, N, Xin, KQ, Okuda, K, Mizukami, H, Ozawa, K et al. (2005). Repair of articular cartilage defect by intraarticular administration of basic fibroblast growth factor gene, using adeno-associated virus vector. Hum Gene Ther 16: 1413-1421.
126. Pascher, A, Steinert, AF, Palmer, GD, Betz, O, Gouze, JN, Gouze, E et al. (2004). Enhanced repair of the anterior cruciate ligament by in situ gene transfer: Evaluation in an in vitro model. Mol Ther 10: 327-336.
127. Madry, H, Cucchiarini, M, Kaul, G, Kohn, D, Terwilliger, EF, Trippel, SB et al. (2004). Menisci are efficiently transduced by recombinant adeno-associated virus vectors in vitro and in vivo. Am J Sports Med 32: 1860-1865.
128. Huard, J, Li, Y, Peng, H and Fu, FH (2003). Gene therapy and tissue engineering for sports medicine. J Gene Med 5: 93-108.
129. Evans, CH, Robbins, PD, Ghivizzani, SC, Wasko, MC, Tomaino, MM, Kang, R et al. (2005). Gene transfer to human joints: Progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102: 8698-8703.
130. Adriaansen, J, Khoury, M, de Cortie, CJ, Fallaux, FJ, Bigey, P, Scherman, D et al. (2007). Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis epub ahead of print.
131. Chuang, YC, Yang, LC, Chiang, PH, Kang, HY, Ma, WL, Wu, PC et al. (2005). Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. Urology 65: 804-810.
132. Mata, M, Glorioso, J and Fink, DJ (2003). Development of HSV-medlated gene transfer for the treatment of chronic pain. Exp Neurol 184 (suppl. 1): S25-S29.
133. Hao, S, Mata, M, Wolfe, D, Huang, S, Glorioso, JC and Fink, DJ (2005). Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 57: 914-918.
134. Wu, CM, Lin, MW, Cheng, JT, Wang, YM, Huang, YW, Sun, WZ et al. (2004). Regulated, electroporation-mediated delivery of pro-opiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats. Gene Ther 11: 933-940.
135. Hao, S, Mata, M, Glorioso, JC and Fink, DJ (2006). HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain 2: 6.
136. Cheng, HY, Pitcher, GM, Laviolette, SR, Whishaw, IQ, Tong, KI, Kockeritz, LK et al. (2002). DREAM is a critical transcriptional repressor for pain modulation. Cell 108: 31-43.
137. Costigan, M and Woolf, CJ (2002). No DREAM, No pain. Closing the spinal gate. Cell 108: 297-300.
138. Macarthur, DG and North, KN (2005). Genes and human elite athletic performance. Hum Genet 116: 331-339.
139. Scott, RA, Moran, C, Wilson, RH, Onywera, V, Boit, MK, Goodwin, WH et al. (2005). No association between Angiotensin Converting Enzyme (ACE) gene variation and endurance athlete status in Kenyans. Comp Biochem Physiol A Mol Integr Physiol 141: 169-175.
140. Niemi, AK and Majamaa, K (2005). Mitochondrial DNA and ACTN3 genotypes in Finnish elite endurance and sprint athletes. Eur J Hum Genet 13: 965-969.
141. Walsh, S, Metter, EJ, Ferrucci, L and Roth, SM (2007). Activin-type II receptor B (ACVR2B) and follistatin haplotype associations with muscle mass and strength in humans. J Appl Physiol 102: 2142-2148.